WHAT: |
The relationship between chromosome alterations and cancer had been debated for more than one hundred years. The first direct link between chromosomal abnormalities to any malignancy came with the discovery of the Philadelphia chromosome in 1960 by Peter Nowell at the Perelman School of Medicine and the late David Hungerford from the Fox Chase Cancer Center’s Institute for Cancer Research. Understanding abnormalities in the replication of the chromosome led to the eventual development of the genetically targeted cancer drug Gleevec in 2001. This symposium celebrates the 50th Anniversary of the discovery of the Philadelphia chromosome and brings us up to date on the genetic basis of cancer, addressing the role of tyrosine kinase enzymes, microRNAs, and immune cells.
|
WHEN: |
Friday, April 30, 2010
10:00am
|
WHERE: |
Stemmler Hall – Dunlop Auditorium
3450 Hamilton Walk, Philadelphia, PA 19104
http://www.pennmedicine.org/hup/vi_files/maps-campus.html
|
SPEAKERS: |
- Mark Greene, MD, PhD, FRCP, University of Pennsylvania School of Medicine
Kinases and Transformation
- Carlo Croce, MD, Ohio State University Medical Center
Causes and Consequences of MicroRNA Dysregulation in Cancer
- Gary Koretzky, MD, PhD, University of Pennsylvania School of Medicine
Signals Regulating Immune Cell Development and Activation
- Mark Lemmon, PhD, University of Pennsylvania School of Medicine
New Lessons in Understanding Regulation of the EGF Receptor Family
- Joseph Schlessinger, PhD, Yale University School of Medicine
Cell Signaling by Receptor Tyrosine Kinases: From Basic Principles to Cancer Therapy
|
Free and open to the public. Please RSVP to Zoe Zampana, 215.615.6510; zampanaz@mail.med.upenn.edu
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.